

LIBIDO



LIBIDO

- + WHAT DO WE MEAN, SPECIFICALLY?
- + IS IT ACTUALLY ASSOCIATED WITH ESTROGEN/HORMONES?
- + IS IT ASSOCIATED WITH AGING?

LIBIDO

- + **Estrogens** — The Women's Health Initiative, a set of randomized trials in over 27,000 postmenopausal patients, found that systemic estrogen with or without progestin therapy did not improve sexual satisfaction and may be harmful


AGE VS. LIBIDO


- + The prevalence of sexual dysfunction among all women is estimated to be between 25% and 63%; the prevalence in postmenopausal women is even higher, with rates between 68% and 86.5%



PAIN

+ VAGINAL CHANGES IN MENOPAUSE







****SOLUTIONS****

+ 1. LUBE, LUBE, LUBE

a. REPLENS

2. VAGINAL ESTROGEN

SOLUTIONS

PELVIC FLOOR PHYSICAL THERAPY



SOLUTIONS



#2 PSYCHOLOGY

- + SEXUAL ACCELERATORS- "Turn ons." Add sexual energy to sexual arousal.
- + SEXUAL BRAKES- "Turn offs." Tend to remove sexual energy from arousal.

ACCELERATORS



BRAKE PUMPERS



MEDICATIONS THAT CAN KILL THE MOOD

- + ANTIDEPRESSANTS (SEROTONIN)
- + ANTIHISTAMINES (FIRST GENERATION)
- + BLOOD PRESSURE MEDICATIONS
- + PAIN MEDICATION (Tylenol and Motrin are SAFE)

WHERE IS VIAGRA FOR WOMEN?

+ WELCOME TO THE "OFF-LABEL" WORLD....

WELLBUTRIN/BUPROPION

- + WORKS BY INCREASING DOPAMINE IN THE BRAIN
- + BENEFITS: WEIGHT LOSS, INCREASED ENERGY
- + POTENTIAL SIDE EFFECTS: INSOMNIA, BLOOD PRESSURE, SEIZURES.

YOUNGSTERS ONLY

vyleesi
(bremelanotide injection)
1.75 mg/0.3 mL | for subcutaneous use only

TESTI



Steps to get Vyleesi

BREMELANOTIDE

- + Two randomized trials in a total of 1247 premenopausal patients with HSDD found that 24 weeks of bremelanotide compared with placebo resulted in more patients with a meaningful increase in sexual desire (51 versus 21 percent) and improvement in sexual satisfaction (57 versus 26 percent)
- + SIDE EFFECTS;
- + COST:

Subcutaneous Solution

1.75 mg/0.3 mL

Vyleesi subcutaneous solution

from \$956.15
for 1.2 milliliters ^

Quantity	Per unit	Price
1.2 (4 x 0.3 milliliters)	\$796.79	\$956.15

Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.

FLIBANSERIN

- + SHORT TERM DECREASE IN SEROTIN AND INCREASES DOPAMIN AND NOREPINEPHRINE IN THE BRAIN
- + SIGNIFICANT SIDE EFFECT PROFILE; SOMNOLENCE, DIZZINESS, HYPOTENSION (LOW BLOOD PRESSURE).
- + This meta-analysis included eight double-blind, randomized trials (three unpublished) with a total of 5914 patients. Flibanserin compared with placebo resulted in a small but statistically significant increase in SSEs per month (pooled mean difference 0.49, 95% CI 0.32-0.67). In terms of absolute benefit, in two trials, there were 0.4 to 1.0 additional SSEs per month with flibanserin from an average baseline of 2.0 to 3.0 per month. In the meta-analysis, measures of sexual desire (Female Sexual Function Index desire, eDiary desire) showed statistically significant improvement, but these changes were modest, and the clinical significance appears small [45]. Scores on the validated measure Patient's Global Impression of Improvement showed minimal improvement to no change. Data from one trial suggest that onset of efficacy with flibanserin starts at four weeks of use.

TESTOSTERONE

- + NOT FDA APPROVED FOR WOMEN
- + WHY ISN'T THE FDA ON BOARD?
- + STUDIES THAT HAVE BEEN DONE
- + A. YOUR LEVEL OF TESTOSTERONE DOESN'T PREDICT SEXUAL FUNCTION/SATISFACTION.
- + MIXED RESULTS....BUT IN GENERAL.....

T-NOT FOR THE FERTILE

- + Labial fusion, clitoromegaly in humans
- + Insulin resistance, low birth weight

TESTOSTERONE


- + SAFETY-
- + TOPICAL-compounded 1% testosterone cream, ointment, or gel.



COMPOUNDED TESTOSTERONE

- + PLAN ON SPENDING \$50.00/MONTH.
- + NOT WITHIN EVERY PROVIDER'S COMFORT LEVEL.

LIBIDO



GET IT PAID FOR

+ R 68.82 DECREASED LIBIDO

+ F 52.22 Female sexual arousal disorder

REFERENCES

Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839.

Ambler DR, Bieber EJ, Diamond MP. Sexual function in elderly women: a review of current literature. Rev Obstet Gynecol. 2012;5(1):16-27. PMID: 22582123; PMCID: PMC3349920.

Pace G, Silvestri V, Gualá L, Vicentini C. Body mass index, urinary incontinence, and female sexual dysfunction: how they affect female postmenopausal health. Menopause 2009; 16:1188.

Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11:367.

<https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women> (Accessed on June 24, 2019).

Borsini F, Evans K, Jason K, et al. Pharmacology of flibanserin. CNS Drug Rev 2002; 8:117.

Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric 2019; 22:429.